Openbookopenbook
Equity
LABFF
+0.0 · +0.00%
USD · PINK

Laboratorios Farmaceuticos Rovi S.A(LABFF) Stock Analysis | Healthcare

USD --+0.00%
Reward47Moderate
Risk14Low
75%Data
Strong 17% profit margin · Revenue down 11% YoY
Defensive Anchor
Market Cap:4.63Bn
ⓘ
Reward Rating
47
Moderate
Reward Assessment
75% data coverage
Bottom 25% of stocksView factors
ⓘ
Risk Rating
14
Low
Risk Assessment
1 metric flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on LABFF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for LABFF, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Laboratorios Farmaceuticos Rovi S.A?

manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally.

LABFF · Verdict

Moderate reward · low risk

LABFF stands out on volatility and cash flow, but watch the valuation signal.

Based on 88% data coverage

LABFF · Verdict

What’s working & what to watch

Strengths 4

  • Volatility95/100

    Top decile vs peers

  • Cash flow85/100

    10% free-cash-flow margin

  • Balance sheet80/100

    Interest covered 73.5×

  • Profitability74/100

    18% net margin · 20% ROE

Watchouts 2

  • Valuation27/100

    P/E 36.8×

  • Growth40/100

    Rev +5.6% CAGR · earnings -3.7%

Model-based scoring. For information only — not financial advice.

What is Laboratorios Farmaceuticos Rovi S.A?

manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 4.63B, and a P/E ratio of 28.9x.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (47)

The scoring profile indicates limited reward potential at this time, with profitability and momentum offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.

LVZPFMid Cap / 4.6B market cap
Livzon Pharmaceutical Group Inc
Compare
INDVMid Cap / 4.6B market cap
Indivior PLC Ordinary Shares
Compare
HKMPYMid Cap / 5B market cap
Hikma Pharmaceuticals PLC ADR
Compare
Company Information
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Market Cap4.63B
P/E Ratio28.9489
Dividend Yield1.03%
Beta0.244
Insider Activity
12M windowNo data
No insider activity data available for this ticker.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.